$PMBSD mkt cap $200k, Marijuana Epilepsy Drug
Ludlow Research Issues Opinion on PMBSD Based on Cannabis-Based Epilepsy Symptom Research, Launch of Migraine Product
SCHOFIELD, Wis., Oct. 15, 2014 /PRNewswire/ -- PuraMed BioScience®, Inc., (PMBSD), a researcher, developer, and marketer of over-the-counter medicinal and healthcare products, announced that Ludlow Research has issued a research opinion of the Company based on the pending launch of its rebranded migraine product, MigraPure, the development of a hemp-based epilepsy symptom treatment, and the Company's current valuation.
The Company recently announced development of an over-the-counter medication using cannabinoid-rich hemp, for the treatment of epilepsy symptoms. Recent studies show CBD to be effective in the treatment of the symptoms of epilepsy.
"As PuraMed prepares to re-launch its natural over-the-counter migraine product as MigraPure and develops its hemp-based formulation, the company could create a medication with wide ranging benefits for people who suffer with epilepsy and who suffer chronic migraines," said Tom Bustamonte, of Ludlow Research.
In addition, the Company recently announced completion of the first batch of its patented, sublingual MigraPure® Advanced Migraine Relief feverfew and ginger gel with an enhanced flavor.
MigraPure Advanced Migraine Relief is a doctor-recommended homeopathic formulation that has been clinically tested (originally tested as LipiGesic® M) by headache experts and found highly effective in the treatment of acute migraine pain and associated symptoms. Packaged in pre-measured UnitDose sachets, MigraPure's gel is administered under the tongue, which allows active ingredients to reach the bloodstream faster and more effectively than traditional oral medications.
PMBSD current has approximately 70 million common shares issued and outstanding, and is fully reporting with the SEC.
Ludlow Research issued their "speculative" opinion on PMBSD based on research in areas of epilepsy symptom treatment using cannabinoid-rich hemp, the pending re-launch of the over-the-counter migraine product, MigraPure advanced migraine relief, and the current low market cap value of the Company, which is just under $300,000.
To download the full report, and access risks, disclosers, and potential outlook visit www.ludlowresearch.com/reports.html
About Ludlow Research
Ludlow Equity Research is a New York based equity research firm focused on providing our clients, and individual readers, with in-depth research coverage and opinions on the small-cap securities market. For over 14 years, we have aimed to provide our subscribers a simple way of evaluating the current and potential value of small-cap stocks, and any risks that may affect those valuations going forward. Our goal is to provide traders with an easy way to make investment decisions based on current and future valuations. Ludlow Equity Research is a division of Ludlow Capital, Inc. www.ludlowresearch.com
Ludlow Research provides research coverage and host of investor awareness services for publicly traded small cap equities.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products, which often work faster, more effectively, and have fewer side effects than their chemical-based counterparts.
In addition to the rebranding of LipiGesic M as MigraPure, PMBS plans to launch additional hemp-based, cannabinoid-enhanced, anti-inflammatory and anxiolytic products as it moves forward in the development of its cannabinoid product line. www.PuramedBioScience.com
AI
